MedPath

Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

Not Applicable
Conditions
Osteoporosis
Registration Number
NCT01246375
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Brief Summary

The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
20
Inclusion Criteria
  1. Man at the minimum age of 60 years.
  2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
  3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria
  1. Usage of systemic steroids more than once during the 12 months prior to the study.
  2. Usage of systemic steroids during the month prior to the study.
  3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Diagnosis of Osteoporosis3
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Tel Aviv medical center

🇮🇱

Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath